Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive ...

Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

AMMAN - Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 ...

Rajiv Onat, India head, digital technology and engineering, Regeneron, acknowledged Telangana’s role in creating a ...

The Philippine Pediatric Society advocates for the approval of a next-generation dengue vaccine to combat the rising dengue ...

The new regional registry for rare disease patients in Campania, inaugurated in January, the multidisciplinary ...

EUROPE: Trump said the EU and other countries have troubling trade surpluses with the United States. He has said the ...

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the ...